Cargando…

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments

PURPOSE: Outcomes of health technology assessments (HTA) are uncertain, and decision-making is associated with a risk. This risk, consisting of the probability of making a wrong decision and its impact, is rarely considered in HTA. This hampers transparent and consistent risk assessment and manageme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grimm, Sabine E., Pouwels, Xavier, Ramaekers, Bram L. T., Wijnen, Ben, Otten, Thomas, Grutters, Janneke, Joore, Manuela A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476369/ https://www.ncbi.nlm.nih.gov/pubmed/34278550 http://dx.doi.org/10.1007/s40273-021-01060-3

Ejemplares similares

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
por: Grimm, Sabine E., et al.
Publicado: (2019)

Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2022)

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2023)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
por: Pouwels, Xavier Ghislain Léon Victor, et al.
Publicado: (2017)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
por: Bindels, Jill, et al.
Publicado: (2015)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2018)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Health technology assessment: a framework
por: Joore, Manuela, et al.
Publicado: (2020)

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem, et al.
Publicado: (2023)

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2022)

Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?
por: de Wit, Maarten, et al.
Publicado: (2020)

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Potential barriers and facilitators for implementation of an integrated care pathway for hearing-impaired persons: an exploratory survey among patients and professionals
por: Grutters, Janneke PC, et al.
Publicado: (2007)

The art and science of communication: tools for effective communication in the workplace
por: Perkins, P S
Publicado: (2008)

Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints
por: Grutters, Janneke P. C., et al.
Publicado: (2007)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

State-of-the-art technologies for precision
Publicado: (2007)

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
por: van Asselt, Thea, et al.
Publicado: (2017)

State of the art in digital audio/video communications
por: Flückiger, François
Publicado: (1997)

Modulators for Terahertz Communication: The Current State of the Art
por: Ma, Z. T., et al.
Publicado: (2019)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

State-of-the-art infrared detector technology
por: Kinch Michael A
Publicado: (2014)

Sensors and Technologies in Spain: State-of-the-Art
por: Pajares, Gonzalo
Publicado: (2014)

Wireless Body Sensor Communication Systems Based on UWB and IBC Technologies: State-of-the-Art and Open Challenges
por: Čuljak, Ivana, et al.
Publicado: (2020)

Steps in implementing a health economic evaluation
por: Guillemin, Francis, et al.
Publicado: (2020)

Cost assessment of health interventions and diseases
por: Fautrel, Bruno, et al.
Publicado: (2020)

State of the Art and Future Perspectives in Advanced CMOS Technology
por: Radamson, Henry H., et al.
Publicado: (2020)

Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments
por: Petersohn, Svenja, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ub4vmquouqqnuofnn4en1l2dpr